menu
    • menu
    [{"orgOrder":0,"company":"Kotobuki Pharmaceutical","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kotobuki Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kotobuki Pharmaceutical \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kotobuki Pharmaceutical \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Kotobuki Pharmaceutical","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kotobuki Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kotobuki Pharmaceutical \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kotobuki Pharmaceutical \/ Kotobuki Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Kotobuki Pharmaceutical

    Menu

    Kotobuki Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kotobuki Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kotobuki Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astellas Launches XOSPATA (Gilteritinib) in Singapore to Treat Adult Leukaemia Patients

                            Details : Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is approved for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.

                            Product Name : Xospata

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2021

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kotobuki Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kotobuki Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myelo...

                            Details : Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is approved for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.

                            Product Name : Xospata

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2020

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth